Otsuka to buy U.S. biopharmaceutical firm Avanir for $3.5 bil.

Otsuka to buy U.S. biopharmaceutical firm Avanir for $3.5 bil.

TOKYO, Japan - Tatsuo Higuchi, president of Otsuka Holdings Co., attends a press conference in Tokyo's Minato Ward on Dec. 2, 2014, on the planned acquisition by its subsidiary Otsuka Pharmaceutical Co. of California-based biopharmaceutical firm Avanir Pharmaceuticals Inc. for $3.54 billion through a tender offer to be followed by a merger. The Japanese nutrition product and drug manufacturer will pay $17 per Avanir share in the takeover bid through its U.S. subsidiary.

  • Product Code
  • ILEA001211374
  • Registered date
  • 2014/12/02 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2014 Kyodo News
  • Media size
  • 1281 × 1701 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 324.18(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

      Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
        U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

        U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

        Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
          TEPCO expects 227 bil. yen pretax profit in FY 2014

          TEPCO expects 227 bil. yen pretax profit in FY 2014

          TOKYO, Japan - Tokyo Electric Power Co. Chairman Fumio Sudo attends a press conference at the company's headquarters in Tokyo on Dec. 17, 2014. TEPCO, which operates the disaster-hit Fukushima Daiichi nuclear plant, said it expects to record a group pretax profit of 227 billion yen for the business year ending March 2015 on the back of deeper cost-cutting, remaining in the black for the second straight year.
            Otsuka to buy U.S. biopharmaceutical firm Avanir for $3.5 bil.

            Otsuka to buy U.S. biopharmaceutical firm Avanir for $3.5 bil.

            TOKYO, Japan - Tatsuo Higuchi, president of Otsuka Holdings Co., attends a press conference in Tokyo's Minato Ward on Dec. 2, 2014, on the planned acquisition by its subsidiary Otsuka Pharmaceutical Co. of California-based biopharmaceutical firm Avanir Pharmaceuticals Inc. for $3.54 billion through a tender offer to be followed by a merger. The Japanese nutrition product and drug manufacturer will pay $17 per Avanir share in the takeover bid through its U.S. subsidiary. (Kyodo)
              Moody's cuts rating on Japan sovereign debt by 1 notch

              Moody's cuts rating on Japan sovereign debt by 1 notch

              TOKYO, Japan - Thomas Byrne, a senior vice president of Moody's Investors Service Inc., holds a press conference in Tokyo on Dec. 1, 2014, after the U.S. rating agency revised downward its credit rating on Japanese sovereign bonds by one notch to A1 from Aa3 with stable outlook, citing uncertainty over the nation's ability to restore its fiscal health.
                Toray agrees on 1 tril. yen supply contract with Boeing

                Toray agrees on 1 tril. yen supply contract with Boeing

                TOKYO, Japan - Akihiro Nikkaku (L), president of Toray Industries Inc., shakes hands with John J. Tracy, chief technology officer of Boeing Co., at a press conference in Tokyo on Nov. 17, 2014. Toray said it has agreed on a new contract worth 1 trillion yen (about $8.7 billion) to supply carbon fiber for Boeing's jets and will begin talks to work together with the U.S. aircraft maker to lower the costs of the lightweight material.
                  Ajinomoto to buy U.S. frozen foods maker Windsor

                  Ajinomoto to buy U.S. frozen foods maker Windsor

                  TOKYO, Japan - Masatoshi Ito (R), president of Ajinomoto Co., and Greg Geib, president of Windsor Quality Holdings, shake hands during a press conference in Tokyo on Sept. 10, 2014. They announced that Japan's Ajinomoto will buy the U.S. frozen foods maker for about $800 million in a bid to grow its presence in the giant North American market.
                    Mizkan completes purchase of Unilever's U.S. pasta sauce business

                    Mizkan completes purchase of Unilever's U.S. pasta sauce business

                    NAGOYA, Japan - Kenji Hasegawa, president of Mizkan Holdings Co., tells a press conference in Nagoya on July 1, 2014, that the Japanese food manufacturer has completed its purchase of the U.S. pasta sauce brands of Anglo-Dutch consumer goods giant Unilever.
                      Renesas to sell display chip unit to Synaptics for 48.5 bil. yen

                      Renesas to sell display chip unit to Synaptics for 48.5 bil. yen

                      TOKYO, Japan - Ikuo Kudo (L), president of display chip maker Renesas SP Drivers Inc., and Rick Bergman, president and chief executive officer of U.S. IT company Synaptics Inc., shake hands during a press conference in Tokyo on June 11, 2014. Struggling electronics maker Renesas Electronics Corp. said it will sell its subsidiary Renesas SP Drivers to Synaptics.